1. Home
  2. MIRM vs STNE Comparison

MIRM vs STNE Comparison

Compare MIRM & STNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$100.65

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo StoneCo Ltd.

STNE

StoneCo Ltd.

HOLD

Current Price

$17.70

Market Cap

4.4B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
STNE
Founded
2018
2012
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.4B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
MIRM
STNE
Price
$100.65
$17.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
8
Target Price
$102.64
$17.50
AVG Volume (30 Days)
733.0K
5.7M
Earning Date
02-26-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
$2,670,485,228.00
Revenue This Year
$55.91
$15.38
Revenue Next Year
$23.97
$6.49
P/E Ratio
N/A
N/A
Revenue Growth
53.66
24.14
52 Week Low
$36.88
$8.64
52 Week High
$105.74
$19.95

Technical Indicators

Market Signals
Indicator
MIRM
STNE
Relative Strength Index (RSI) 64.68 63.68
Support Level $97.49 $15.85
Resistance Level $105.74 $18.19
Average True Range (ATR) 3.71 0.79
MACD -0.79 0.17
Stochastic Oscillator 62.01 79.50

Price Performance

Historical Comparison
MIRM
STNE

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About STNE StoneCo Ltd.

StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.

Share on Social Networks: